ArticleJournal of fungi (Basel, Switzerland)2019
Antifungal Resistance in Clinical Isolates of
Article in Journal of fungi (Basel, Switzerland), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Old drugs, new weapons: current trends in repurposing therapies against antimicrobial resistance.Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques · 2026Review
- Efficacy and safety of voriconazole and caspofungin for the treatment of invasive pulmonary aspergillosis in critically ill patients in China.Frontiers in cellular and infection microbiology · 2025Article
- What do We Know about Cryptic Aspergillosis?Microorganisms · 2024Review
- Interplay of Cytokines and Chemokines in Aspergillosis.Journal of fungi (Basel, Switzerland) · 2024Review
- Article
- Epidemiology and antifungal susceptibilities of clinically isolatedEpidemiology and infection · 2023Article
- Specific Focus on Antifungal Peptides against Azole ResistantJournal of fungi (Basel, Switzerland) · 2022Review
- Clinical and mycological investigations of post-COVID-19 acute invasive fungal sinusitis.Laryngoscope investigative otolaryngology · 2022Article
- Calcimycin InhibitsACS infectious diseases · 2022Article
- Experience of Isavuconazole as a Salvage Therapy in Chronic Pulmonary Fungal Disease.Journal of fungi (Basel, Switzerland) · 2022Article
- COVID-19-Associated Fungal Infections: An Urgent Need for Alternative Therapeutic Approach?Frontiers in microbiology · 2022Review
- Genome-Wide Association Analysis for Triazole Resistance inPathogens (Basel, Switzerland) · 2021Article
- Emergence of Triazole Resistance inCurrent fungal infection reports · 2021Review
- Update on Respiratory Fungal Infections in Cystic Fibrosis Lung Disease and after Lung Transplantation.Journal of fungi (Basel, Switzerland) · 2020Review
- Drug-Resistant Fungi: An Emerging Challenge Threatening Our Limited Antifungal Armamentarium.Antibiotics (Basel, Switzerland) · 2020Review
- Protective Efficacy of Lectin-Fc(IgG) Fusion Proteins In Vitro and in a Pulmonary Aspergillosis In Vivo Model.Journal of fungi (Basel, Switzerland) · 2020Article
- Distribution ofTherapeutic advances in infectious diseaseReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aspergillosis is a set of very frequent and widely distributed opportunistic diseases. Azoles are the first choice for most clinical forms. However, the distribution of azole-resistant strains is not well known around the world, especially in developing countries. The aim of our study was to determine the proportion of non-wild type strains among the clinical isolates of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.